Separately, Panmure Gordon restated a buy rating and issued a GBX 380 ($4.96) price target on shares of Midatech Pharma PLC in a report on Wednesday, September 21st.
Midatech Pharma PLC (LON:MTPH) opened at 130.00 on Friday. Midatech Pharma PLC has a 12-month low of GBX 100.51 and a 12-month high of GBX 285.00. The firm’s 50-day moving average is GBX 144.86 and its 200 day moving average is GBX 140.82. The firm’s market cap is GBX 43.60 million.
About Midatech Pharma PLC
Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.
Receive News & Ratings for Midatech Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.